High-dose ibuprofen linked to small increased CV risk, EMA committee confirms
This article was originally published in Scrip
A European Medicines Agency committee has confirmed that there is a small increase in the risk of cardiovascular problems such as heart attacks and stroke in patients taking high doses – 2,400mg or more – of ibuprofen, and has recommended that the labelling of products containing the anti-inflammatory drug should be updated to reflect this risk.
You may also be interested in...
Rx-to-OTC switches of the painkillers dexibuprofen and single-pill combinations of ibuprofen and paracetamol as well as the cough medicine levodropropizine, all for oral use, will be considered at the next German Expert Committee for Prescription meeting on 13 July.
Regulatory flexibilities such as rolling review, conditional marketing authorizations and possibly an EU emergency use authorization will play a key part in the EU’s plans to identify and approve promising new coronavirus treatments.
The European Commission’s plans for overhauling the EU medicines legislation have elicited a number of proposals from the pharmaceutical industry to improve the regulatory framework, including streamlining the committee system, improving the use of expedited evaluation pathways, and expanding the European Medicines Agency’s role in assessing drug/device combination products.